Most people who undergo a thorough check-up come away with manageable findings — a lipid profile that needs attention, a vitamin deficiency to correct, a fitness level to improve. But a small share — how many depends on which tests are done; in one cohort of about 2,000 people screened with whole-body MRI, about 2% had a highly suspicious finding and about 1% a confirmed cancer — will have a finding that is genuinely serious: a suspicious mass on imaging, a biopsy result that needs oncologic follow-up, a cardiac finding that requires intervention.
The fear of exactly this moment keeps many people from screening at all. Knowing what should happen next — and what a good process looks like — makes it easier to face.
Three kinds of findings
Findings fall roughly into three groups, and each calls for a different pace:
- Urgent: findings that need action within days — for example a high-grade suspicious mass, a dangerous heart rhythm or a critically abnormal lab value. These should be communicated immediately and lead to a referral that same week.
- Needs work-up: findings that are not yet a diagnosis but must be clarified — an indeterminate nodule, a polyp awaiting histology, a borderline biopsy. Here the key is a clear plan with dates, not speed at any price.
- Incidental: unexpected findings that are usually harmless, such as small cysts or tiny nodules. Many need only a defined follow-up interval or no action at all. Over-investigating them carries its own risks — the problem of overdiagnosis is well documented.
What a good process looks like
You hear it from a physician, not from a report. A serious finding should not reach you first via email or a patient portal. It deserves a conversation — in person or at least by phone or video — with enough time for your questions.
Someone owns the next step. The most dangerous gap in medicine is the one between "finding" and "follow-up". A good process names who is responsible for arranging the next appointment, who receives the results, and when you will hear back.
You receive complete records. Reports, imaging data, pathology results and a clear physician letter belong to you. They make it possible to continue care elsewhere and to seek a second opinion without repeating tests.
There is a checkpoint. A follow-up call or appointment a few weeks later — to confirm that referrals have happened and nothing has fallen through the cracks — is a simple safeguard that is easy to ask for.
Questions to ask your doctor
- What exactly was found, and how certain is it?
- Is this urgent, does it need further work-up, or is it likely incidental?
- What is the next step, who arranges it, and by when?
- What happens if I wait — and what happens if I act now?
- Can I have copies of all reports and images?
Second opinions and timelines
For serious diagnoses, especially before major surgery or cancer treatment, a second opinion is reasonable and routine; good physicians do not take offence. In most work-up situations a few days spent on a second opinion do not change the outcome — but for truly urgent findings, the second opinion should run in parallel with, not instead of, the first steps. Ask how much time you safely have.
Coping with uncertainty
The weeks between a suspicious finding and a definitive answer are often the hardest part. It helps to have a written plan with dates, one contact person for questions, and someone you trust to accompany you to appointments. Many findings that look worrying at first turn out to be benign.
Why looking is still worth it
The fear of "what if they find something?" is one of the most common reasons people hesitate to do a comprehensive health assessment. It's understandable. But consider the alternative: the finding exists whether or not you look for it. Finding it earlier — when treatment options are better, when the disease is at an earlier stage, when the prognosis is fundamentally different — is the entire point of preventive medicine.
A thin, early melanoma (stage IA) has a 10-year melanoma-specific survival of roughly 95–98%. Once it has spread to the lymph nodes, 10-year survival ranges from about 88% to as low as 24%, depending on the substage — and in advanced melanoma, even with the best current immunotherapy, about half of patients die of the disease within ten years. The difference is timing. And timing requires looking. (More on this in the article on skin cancer and dermatoscopy.)
What matters is that a finding never leaves you alone with it: a physician who knows the full picture, a clear next step, and a path forward that you choose.
References
- Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-613.
- Esserman LJ, Thompson IM Jr, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013;310(8):797-798.
- Hu YS, et al. Applying ONCO-RADS to whole-body MRI cancer screening in a retrospective cohort of asymptomatic individuals. Cancer Imaging. 2024;24:22.
- Gershenwald JE, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.
- Wolchok JD, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11-22.
This article is general information and not individual medical advice. Decisions about tests and treatment belong in a conversation with your own physician.